We test and we share. By providing accessible clinical trial information, we are committing to helping people - medical practitioners, patients and their families - improving their knowledge of healthcare testing and results. We publish the results of our clinical trials openly as part of our global transparency policy. Find here basic information on the registration and results of our clinical trials.
Closer to patients
We want to be always a step ahead to transform your life, that’s why we have developed a digital application for patients who are included in our clinical studies: the Skincare App. Available since the end of 2019, via their mobile phone patients can share their evolution with the clinical sites by sending data and receiving interactive content about their disease progression in a convenience and cost-effective way in addition to educational content that allows them to adopt healthy tips.
Our transparency policy
Transparency and openness leads to a better healthcare. Our transparency policy follows the recommendations of the European Federation of the Pharmaceutical Industries & Associations (EFPIA), the Pharmaceutical Research & Manufacturers of America (PhRMA) joint Position Papers on the Disclosure of Clinical Trial Information via Clinical Trials Registries & Databases and the Principles for Responsible Clinical Trial Data Sharing.
We are committed to facilitating any study data request submitted by qualified scientific or medical researchers for medicines and indications approved in the USA and the EU on or after January 2014.
All requests will be reviewed independently on a case-by-case basis.
Good practices in clinical trials, our standard
We carry out our global clinical trials efficiently and qualitatively according to internationally-accepted scientific and ethical standards. Clinical trials are performed in line with authorities’ requirements in the countries where the trials are performed, as well as following European Directives & Guidelines, such as Good Clinical Practices from the International Conference of Harmonization, and FDA GCP regulations contained in the 21 Code of Federal Regulations.
Please keep in mind that the information on this website is not intended to replace advice from healthcare professionals. Patients should always seek medical advice before starting or changing their treatment. Healthcare professionals should consult the approved labelling for the patient's country to ensure that they receive the most up-to-date and appropriate information according to local requirements.